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Abstract: In the experimental autoimmune encephalomyelitis (EAE) mouse model of optic neuritis,
we recently demonstrated that diet supplementation with a balanced mixture of fatty acids (FAs),
including omega 3 and omega 6, efficiently limited inflammatory events in the retina and prevented
retinal ganglion cell (RGC) death, although mechanisms underlying the efficacy of FAs were to
be elucidated. Whether FAs effectiveness was accompanied by efficient rescue of demyelinating
events in the optic nerve was also unresolved. Finally, the possibility that RGC rescue might result in
ameliorated visual performance remained to be investigated. Here, the EAE model of optic neuritis
was used to investigate mechanisms underlying the anti-inflammatory effects of FAs, including
their potential efficacy on macrophage polarization. In addition, we determined how FAs-induced
rescue of RGC degeneration was related to optic nerve histopathology by performing ultrastructural
morphometric analysis with transmission electron microscopy. Finally, RGC rescue was correlated
with visual performance by recording photopic electroretinogram, an efficient methodology to
unravel the role of RGCs in the generation of electroretinographic waves. We conclude that the
ameliorative effects of FAs were dependent on a predominant anti-inflammatory action including
a role on promoting the shift of macrophages from the inflammatory M1 phenotype towards the
anti-inflammatory M2 phenotype. This would finally result in restored optic nerve histopathology and
ameliorated visual performance. These findings can now offer new perspectives for implementing
our knowledge on the effectiveness of diet supplementation in counteracting optic neuritis and
suggest the importance of FAs as possible adjuvants in therapies against inflammatory diseases of
the eye.
Keywords: optic neuritis; myelin oligodendrocyte glycoprotein; neuroinflammation; macrophage
polarization; demyelination; photopic ERG.
1. Introduction
The recent trend in ocular pathologies is to use medicinal natural products, which may offer
the same efficacy of conventional drugs without so many side effects. In particular, nutritional
approaches may contribute to counteract eye diseases with a major inflammatory component as
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an increasing amount of scientific data highlights the ability of specific nutrients to cross the blood
retinal barrier and to modulate inflammatory pathways that account for eye diseases [1]. Among diet
supplements, fatty acids (FAs) including omega 3 and omega 6, are extensively investigated in terms
of prophylactic benefits, potential harms, and optimal use in ocular pathologies, but their benefits
are often controversial. For instance, the Age-Related Disease Study 2 (AREDS2) seems to exclude
preventive effects of omega-3 FAs against dry age-related macular degeneration (AMD), although
disregarding a role of FAs in AMD progression should be reconsidered [2]. Indeed, in a murine
model of dry AMD [3], we recently demonstrated that diet supplementation with a calibrated mixture
of the long chain omega 3 and omega 6 FAs drastically ameliorates complement-mediated effects,
thus decreasing macrophage recruitment and the production of pro-inflammatory and angiogenic
cytokines, which in turn improve degenerative events in the retina and the choroid [4]. In addition,
using the experimental autoimmune encephalomyelitis (EAE) mouse model of optic neuritis, we
found that daily gavage with a FAs mixture delays the onset of EAE and prevents, at least in part,
the death of retinal ganglion cells (RGCs) through a major anti-inflammatory action [5]. This has
been shown to occur without affecting the infiltration of macrophages in the retina thus eventually
preserving their correct release of trophic and growth factors that are known to prevent optic nerve
degeneration [6]. Ameliorative effects of FAs are in line with previous findings in the EAE model
demonstrating that a combination of FAs, antioxidants, free radicals, and amino acids protects the
optic nerve from demyelination and promotes the formation of the myelin sheath [7].
Understanding the mechanisms underlying the anti-inflammatory action of FAs can offer new
perspectives not only for implementing our knowledge on the effectiveness of diet supplements in
optic neuritis, but also for expanding a complementary nutritional intervention in multiple sclerosis
(MS). In addition, whether FAs efficacy is accompanied by a rescue of demyelinating events in the optic
nerve remains to be clarified. Finally, the possibility of correlating RGC rescue with improved visual
performance may add further value to the use of FAs since a few neuroprotectants have been shown to
successfully rescue RGC function [8–10]. In the present study, the EAE model of optic neuritis was used
to clarify mechanisms underlying the anti-inflammatory effects of FAs including an investigation of the
possibility that FAs may shift macrophage polarization from the M1 inflammatory phenotype towards
the anti-inflammatory M2 phenotype [11]. To this aim, in retinal homogenates, we evaluated the effect
of FAs on (i) the transcript level of M1-and M2-related markers, (ii) transcription factors related to
M1/M2 activation, and (iii) interleukin (IL)-10 and Arginase-1 (Arg-1) that are well-established markers
of the M2 phenotype [11]. In addition, we determined how FAs-induced rescue of RGC death may be
related to ameliorated optic nerve histopathology by performing ultrastructural morphometric analysis
by transmission electron microscopy. Finally, we aimed at correlating RGC rescue with visual function
by determining the effect of FAs on the photopic negative response (PhNR) of an electroretinogram
(ERG), an efficient tool to unravel the role of RGCs in the generation of electroretinographic waves [12].
2. Materials and Methods
2.1. Animals
Experiments were carried out in accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health, the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research, the Italian guidelines for animal care (DL
26/14), and the European Communities Council Directive (2010/63/UE). The experimental procedures
were approved by the Commission for Animal Wellbeing of the University of Pisa (Permit Number:
0009069/2014). All efforts were made to reduce animal suffering and the number of animals. C57BL/6J
mice were purchased from Charles River Laboratories Italy (Calco, Italy), mated in-house to a breeding
colony in a regulated environment (23 ± 1 ◦C, 50 ± 5% humidity) with a 12 h light/dark cycle (lights
on at 08:00 a.m.) and provided with a standard diet and water ad libitum. In the present study,
36 females (8 week-old) were used as more susceptible than males to develop MS [13]. Indeed, MS
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as many other diseases with an autoimmune etiology have a skewed sex distribution with females
being affected more frequently than males presumably due to hormonal and gender influences on
the immune response, as well as to genetic influences [14]. On the other hand, the susceptibility to
develop experimental MS linked to sex differences has been long debated in the mouse model [15].
In addition, sex restriction in animal studies should be taken cautiously to avoid potential pitfalls as
indicated in the European Commission funding program Horizon 2020.
2.2. Induction of EAE
As described previously, mice were anesthetized by isoflurane and 18 received subcutaneous
injections of 200 µg myelin oligodendrocyte glycoprotein (MOG) peptide (MOG35–55; Anaspec,
Freemont, CA, USA) emulsified in Complete Freund’s Adjuvant (CFA; Sigma-Aldrich, St. Louis,
MO, USA), containing 2.5 mg/mL Mycobacterium tuberculosis. Eighteen mice (from now on referred
as controls) were injected with an equal volume of phosphate-buffered saline (PBS) and CFA.
All animals received 200 ng pertussis toxin (Sigma-Aldrich, St Louis, MO, USA) in 0.1 mL PBS
by intraperitoneal injection at 0 and 48 h post immunization. The EAE model of MS in the C57BL/6J
mouse strain approximates the human disease although no peculiar susceptibility of this strain has
been demonstrated. As determined by clinical EAE scores, C57BL/6J mice treated with MOG were
found to develop an ascending paralysis that was either monophasic or chronically nonremitting with
first symptoms after 9 to 14 days, disease maximum approximately 3 to 5 days after disease onset and
partial symptom recovery over the next 10 to 20 days [16]. Clinical EAE scores were graded blindly
and daily using an established standard scoring system [17]. Nine MOG-treated mice, which were
sacrificed at the day 16 postimmunization corresponding to the score 2 ± 0.5 when optic neuritis
becomes well established [18], were compared with nine control mice. Six mice for each group were
used for electroretinography before sacrifice.
2.3. Dietary Supplementation
In line with a previous study [5], 9 MOG-treated mice and nine controls received by oral gavage
(starting from the day of immunization until the day 16 when the animals were sacrificed) a mixture
of saturated and unsaturated FAs including 20% of saturated FAs, while 17.5% of unsaturated FAs.
Of this mixture, 3.75 mg suspended in 200 µL of 10% sucrose in water were administered to the animals.
The mixture composition was described previously [5].
2.4. Isolation of Total RNA and Proteins
Mice were deeply anesthetized and euthanized by cervical dislocation. Retinas were rapidly
dissected and stored at −80 ◦C until use. For each analysis, nine independent samples, each
containing two retinas from two mice per experimental condition were used. Total RNA and proteins
were extracted using the AllPrep RNA/Protein Kit (Qiagen, Valencia, CA, USA) according to the
manufacturer instructions.
2.5. Quantitative Real Time PCR
First-strand cDNA was generated from 1 µg of total RNA (QuantiTect Reverse Transcription Kit,
Qiagen, Valencia, CA, USA). Real-time PCR amplification was performed with SsoAdvanced Universal
SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA) on a CFX Connect Real-Time PCR
detection system and software CFX manager (Bio-Rad Laboratories, Hercules, CA, USA). qPCR primer
sets for C-X-C motif chemokine (CXCL)-10, CXCL-11, IL-12, IL-23, C-C motif chemokine (CCL)-2,
CCL-22, cluster of differentiation-163 (CD-163), and Arg-1 were chosen to hybridize to unique
regions of the appropriate gene sequence (see Table S1 for a complete list of assayed genes and
primers). Amplification efficiency was near 100% for each primer pair (Opticon Monitor 3 software,
Bio-Rad Laboratories, Hercules, CA, USA). Target genes were assayed concurrently with Rpl13a:
a gene encoding ribosomal protein L13A. Samples were compared using the relative threshold cycle
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(Ct Method). The increase or decrease (fold change) was determined relative to control mice after
normalization to Rpl13a. All reactions were performed in triplicate.
2.6. Western Blot
Samples containing 30 µg of proteins were subjected to SDS-PAGE, and β-actin was used as
loading control. Gels were transblotted onto a PVDF membrane, and the blots were blocked in 3%
skim-milk for 1 h at room temperature, followed by incubation overnight at 4 ◦C with antibodies
listed in Table S2. Blots were incubated for one hour at room temperature with HRP-conjugated
secondary antibodies (1:5000) and developed with Clarity Western enhanced chemiluminescence
substrate (Bio-Rad Laboratories, Inc., Hercules, CA, USA), images were acquired (ChemiDoc XRS+;
Bio-Rad Laboratories, Inc., Hercules, CA, USA), and the optical density (OD) of the bands was
evaluated (Image Lab 3.0 software; Bio-Rad Laboratories, Inc., Hercules, CA, USA). The data were
normalized to the corresponding OD of β-actin, the signal transducer and activator of transcription 3
(STAT3) or the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) as appropriate.
All experiments were performed in duplicate.
2.7. Electron Microscopy and Quantitative Analysis
After extraction, optic nerves were fixed by immersion in Karnofsky’s solution and stored in the
fixative solution for 3 days at 4 ◦C. Samples were rinsed in 0.1 M cacodylate buffer, postfixed in 1%
osmium tetroxide, dehydrated in ascending dilution series of acetone, and then embedded in Epon 812.
Semithin sections were cut to evaluate quality and orientation of the tissue. Ultrathin cross-sections of
the optic nerves were prepared and mounted on grids, stained with UranyLess TEM staining, and
examined under a JEM 1010 electron microscope (Jeol, Tokyo, Japan) at 20 kV and 50 kV. Images were
captured using a CCD digital camera. For analysis of axon myelinated proportions [19], 10 regions
of interest (ROIs), randomly taken in the subcentral and subperipheral areas of the four optic nerve
quadrants (nasal, temporal, dorsal, or ventral) for each sample (five optic nerves for each experimental
group), were imported into NIH Fiji and all axons within the ROIs were quantified as myelinated
or nonmyelinated. The g-ratio is defined as the ratio of the inner axonal diameter to the total outer
diameter; is a highly reliable ratio for assessing axonal myelination [20]. It was calculated using
digitalized images that were imported into NIH Fiji. For each animal, 30–50 myelinated axons
were measured.
2.8. Electroretinography
Full-field ERG was recorded using a Ganzfeld stimulator (Biomedica Mangoni, Pisa, Italy).
After overnight dark adaptation, mice were prepared for recording under dim red light and
anesthetized by intraperitoneal injection of Avertin. Pupils were dilated with 0.5% atropine, the
cornea was intermittently irrigated with saline solution to prevent clouding of the ocular media, and
a heating pad was used to keep the body temperature at 37 ◦C. The ERG responses were recorded
through silver/silver chloride corneal electrodes and a forehead reference electrode, and a ground
electrode was placed on the tail. Photopic, cone-mediated responses were recorded following 10-min
light adaptation on the background light intensity of 30 cd/m2. Recordings were obtained at the light
intensity of 3 cd-s/m2. From each animal, 10 waveforms were recorded and the values were averaged.
The Photopic Negative Response (PhNR) was identified as the first negative deflection after the b-wave
and its amplitude was calculated relative to baseline (0 µV). The values of PhNR amplitudes were
compared among the groups.
2.9. Statistical Analysis
All data were analyzed by the Shapiro–Wilk test to certify normal distribution. Statistical
significance was evaluated with Prism 5.03 (GraphPad software, San Diego, CA, USA) using one-way
analysis of variance (ANOVA) followed by Newman Keuls’ multiple comparison post-test or two-way
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ANOVA followed by Bonferroni’s multiple comparison post-test as appropriate. After statistical
analysis, the data from different experiments were plotted and averaged in the same graph.
Results were expressed as the mean ± standard error of the mean S.E.M. of the indicated n values.
Differences with p < 0.05 were considered significant.
3. Results
3.1. Supplementation with FAs Shifts M1 Macrophages toward M2 Phenotype
We investigated whether FAs could affect macrophage polarization by evaluating the transcript
levels of M1- or M2-related markers in retinal homogenates. Indeed, macrophages are polarized
toward an M1 phenotype in response to pro-inflammatory stimuli, whereas M2 macrophages display
anti-inflammatory characteristics as IL-10 secretion or upregulated levels of the scavenger receptor
CD-163 [11]. In respect to controls, MOG significantly increased both M1-related markers including
CXCL-10, CXCL-11, IL-12, and IL-23 (Figure 1A–D) and M2-related markers including CCL-2, CCL-22,
CD-163, and Arg-1 (Figure 1E–H). In particular, CXCL-10 (Figure 1A), CXCL-11 (Figure 1B), IL-12
(Figure 1C), IL-23 (Figure 1D), CCL-2 (Figure 1E), CCL-22 (Figure 1F), CD-163 (Figure 1G), and
Arg-1 (Figure 1H) were increased by 3.3-, 3.2-, 2.8-, 2.5-, 2.8-, 2.7-, 3.0-, and 2.0-fold (p < 0.001).
Supplementation with FAs did not affect the levels of these markers in controls. In MOG-treated
mice, upregulated levels of M1-related markers were significantly decreased by FAs, while additional
increase of M2-related markers was determined after FAs supplementation. In particular, FAs reduced
levels of CXCL-10, CXCL-11, IL-12, and IL-23 by 1.6-, 1.5-, 1.4-, and 1.4-fold (p < 0.001), whereas
they increased levels of CCL-2, CCL-22, CD-163, and Arg-1 by 1.5-, 1.3-, 1.3-, and 1.8-fold (p < 0.001).
To evaluate a possible predominance of M2 over M1 macrophages, we analyzed the ratio of the mean
values of M2 to M1. Ratio values of >1 indicated M2 predominance, while ratio values of <1 indicated
M1 predominance [21,22]. The mRNA ratio in controls was standardized at 1. As shown in Figure 1I–L,
after supplementation with FAs, for all markers analyzed, the ratio of M2 to M1 was >1 suggesting an
M2 predominance.
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Figure 1. Dietary supplementation with fatty acids (FAs) reduces upregulated levels of M1-related 
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C-C motif chemokine (CCL)-2 (in E), CCL-22 (in F), cluster of differentiation-163 (CD-163, in G), and
arginase-1 (Arg-1, in H). Transcript levels were evaluated in retinal homogenates from control and
oligodendrocyte glycoprotein (MOG)-treated mice, without or with FAs supplementation by relative
quantification with quantitative real-time PCR (qPCR). Data were analyzed by the formula 2−∆∆CT
using ribosomal protein L13A (Rpl13a) as the internal standard. Ratio of the mean values of CCL-2 to
CXCL-10 (I); CCL-22 to CXCL-11 (J); CD-163 to IL-12 (K); and Arg-1 to IL-23 (L). Data are shown as the
mean± S.E.M. (n = 9 for each experimental group). * p < 0.01; ** p < 0.001 versus control. § p < 0.01;
§§ p < 0.001 versus MOG (One way ANOVA followed by the Newman–Keuls multiple comparison
post-hoc test). White bars, control mice; dashed bars, control mice with FAs supplementation; black
bars, MOG-treated mice; grey bars, MOG-treated mice with FAs supplementation.
Western blotting experiments were also performed in order to evaluate the effect of FAs
administration on transcription factors related to M1/M2 transition. As shown in Figure 2, in
respect to controls, MOG decreased by 3.1-fold (p < 0.001) the phosphorylation of STAT3 at
Tyr705, an important M2-related transcription factor [23], while increased by 2.8-fold (p < 0.001) the
phosphorylation of NF-κB at Ser276, a key transcription factor related to macrophage M1 activation [24].
FAs supplementation did not affect the levels of these factors in controls, whereas, in MOG-treated
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mice, FAs increased the phosphorylation of STAT3 by 3.6-fold (p < 0.001), while decreased the
phosphorylation of NF-κB by 1.4-fold (p < 0.001).
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In additional experiments, we determined whether FAs might affect the levels of IL-10 and Arg-1,
both well-established markers of M2 phenotypes [11]. As shown in Figure 3, MOG decreased both
IL-10 and Arg-1 proteins by 1.9- and 2.1-fold (p < 0.001). FAs supplementation did not affect the levels
of these markers in controls. In MOG-treated mice, FAs significantly increased the levels of both IL-10
(1.9-fold, p < 0.001) and Arg-1 (2.4-fold, p < 0.001).
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3.2. Supplementation with FAs Counteracts Optic Nerve Damage
We studied the optic nerve of EAE animals using transmission electron microscopy and analyzed
the degree of demyelination, and the putative myelin-protecting effect of FAs. As compared to
control mice without or with FAs supplementation (Figure 4A,B), in MOG-treated mice, the optic nerve
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revealed evident demyelinating processes with nonmyelinated axons (arrows), thinly myelinated axons
(arrowheads), and additional signs of myelin changes including delamination (asterisks) (Figure 4C).
In MOG-treated mice with FAs supplementation, optic nerve myelination appeared almost comparable
to that in controls with normally myelinated fibers, but also apparent myelinolysis and scattered thinly
myelinated axons (arrows in Figure 4D). Higher-magnification images in control mice without or with
FAs supplementation show myelinated axons of round-ovoid sectional profiles with microtubules
and neurofilaments dispersed into the axoplasm. Surrounding the axons, myelin was found to
remain compact with a regular periodicity without intramyelinic lacunae or vacuoles (Figure 4E,F).
In MOG-treated mice without FAs supplementation, fibers revealed evident myelin changes including
high levels of lamellar separation and widening (arrows in Figure 4G). In MOG-treated mice with FAs
supplementation, fibers appeared round-ovoid shaped and showed almost compact myelin with a
regular periodicity (arrow in Figure 4H). Morphometric analysis of the optic nerve fibers revealed
a significant reduction of the number of myelinated fibers in MOG-treated mice as compared to
controls without or with FAs supplementation (p < 0.001; Figure 4I). FAs administration prevented the
demyelinating processes in the optic nerve and almost restored the number of myelinated fibers to that
in control mice. As shown in Figure 4J, FAs supplementation to control mice did not affect the mean
g-ratio of the myelinated axons whereas a significant increase could be observed in MOG-treated mice
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3.3. Supplementation with FAs Prevents the Reduction of PhNR Amplitude
We asked the question of whether the efficacy of FAs on RGC survival was associated with
ameliorated retinal function by analyzing the amplitude of the PhNR, a sensitive marker of the
inner retinal function [25–27]. PhNR amplitude is altered in several retinal pathologies involving
RGCs and including, among others, glaucoma, diabetic optic nerve atrophy, and optic neuritis [12].
The amplitude of the PhNR is proportional to the number of functional RGCs [28–32]. As shown in
Figure 5, the amplitude of the PhNR was significantly reduced in MOG-treated mice by approximately
60% as compared to control mice (p < 0.01). FAs administration almost prevented the reduction in
PhNR amplitude.Nutrients 2018, 10, x FOR PEER REVIEW  9 of 15 
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4. Discussion
D et supplements enriched in omega-3 FAs are today available on the market and are used in
patients with MS because of their possible role in restoring MS-associated inflammatory processes [33].
Although information in models of optic neuritis are scarce, neuroprotective effects of omega-3 FAs on
RGC degeneration have been demonstrated in animal models of optic nerve crush [34] and results
in the EAE model are limited to the demonstration of ameliorative effects of FAs on optic nerve
inflammation [7,35,36]. On th oth r hand, the C57BL/6 mouse model of MOG-induced EAE alt ough
exte siv ly used as a mod l of MS does not mi ic the human disease. Indeed, approximately 85%
of patients with MS display a relapsing-remitting disease that is not mirrored by the EAE mo el [37]
although diet supplements enriched in omega-3 FAs have been positively used in MS patients [33].
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As shown by our previous and present results, diet supplementation with FAs efficiently
counteracts the effects of MOG when its administration starts the day of immunization. This protocol
is in line with previous studies in which diet supplements are given after the pathology has been
induced by MOG [5] although, the possibility exists that the incorporation of FAs into the diet before
MOG-induction may be viewed as a preventive measure. Indeed, recent epidemiologic studies have
reported a decreased incidence of MS among individuals with high intake of PUFAs [38–40] although
conflicting results on a possible relationship between PUFA intake and decreased MS risk are also
reported [41].
Our recent findings that in the EAE model, dietary supplementation with a mixture including
omega 3 and omega 6 FAs results in neuroprotective effects on RGCs through a major anti-inflammatory
action [5] opens an interesting field of investigation aimed at implementing the use of FAs as possible
adjuvants in therapies against inflammatory diseases of the eye. In this respect, the fact that FAs
drastically reduce inflammatory events in the retina, but do not affect its macrophage infiltration,
suggests the possibility that they may indeed shift the M1 phenotype towards the M2 without
intervening on the release of trophic factors that play an important role in counteracting optic nerve
degeneration [6].
It is hypothesized that the transition from the pro-inflammatory M1 phenotype to the regulatory
or anti-inflammatory M2 phenotype can lead to tissue repair and restoration of improved functional
outcome [11]. As demonstrated here, FAs act in the retina by modulating the phenotype of
macrophages, decreasing their pro-inflammatory activity and proportionally increasing their tissue
restoring capabilities with a positive effect on neuronal rescue in line with finding that the M1/M2
phenotype balance plays an important role in optic neuritis progression [42]. Of the M1-related
markers, IL-12 and IL-23 play a critical role in EAE development by inducing the release of CXCL-10
and CXCL-11 [43] that are both involved in macrophage recruitment [44]. Among M2-related markers,
CCL-2 promotes axon regeneration in a rat spinal cord injury model [45], whereas CCL-22 contributes
to the recruitment of T cells with anti-inflammatory function in the EAE model [46]. The fact that FAs
supplementation shifts the macrophage balance towards the M2 phenotype is in line with the finding
that in a rat model of optic neuropathy, supplementation with omega-3 FAs decreases RGC loss by
regulating macrophage phenotype [47].
Additional evidence that FAs may act by promoting the shift towards the M2 phenotype originates
from the demonstration that FAs are shown here to increase the levels of transcription factors related to
M2 activation. Indeed, transcriptional regulation is central to the differential speciation of macrophages,
and several major pathways have been described as essential for subset differentiation. Among them,
STAT3 is the key transcription regulator of IL-10, a major anti-inflammatory mediator [48]. In particular,
IL-10 binds the IL-10 receptor complex thus resulting in JAK1-mediated activation of STAT3 and
repression of proinflammatory cytokines [49]. NF-kB, in contrast, orchestrates the expression of many
inflammatory genes in response to various physiological and environmental stimuli [50]. As shown
here, MOG decreases the phosphorylation of STAT3, while increasing the phosphorylation of NF-κB in
line with previous studies demonstrating that in the EAE model, reduced activity of STAT3 increases the
disease severity that is, in contrast, drastically ameliorated by NF-κB inactivation [51]. As also shown
by the present results, supplementation with FAs almost reinstates control levels of pSTAT3, while
its effects on pNF-kB appear less pronounced albeit significant. In this line, in rats with experimental
brain injury, omega-3 FAs have been shown to inhibit NF-kB thus attenuating microglia-induced
inflammation [52]. As a further evidence that FAs play a key role on macrophage polarization, we
found that diet supplementation with FAs prevents MOG-induced downregulation of IL-10 and Arg-1;
both of which are well-established markers of M2 phenotype and are both associated with attenuation
of inflammation [11]. In particular, IL-10 is an important mediator of inflammation resolution through
a major repression of proinflammatory cytokines [53], while Arg-1 promotes cytokine production thus
contributing to resolution of inflammation and tissue repairing [54,55].
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Overall, our results confirm the critical role of macrophages in optic neuritis and demonstrate for
the first time that M2 macrophages become predominant after diet supplementation with FAs although
further investigations are required to understand the mechanisms underlying the macrophage shift.
In this respect, targeting M2 macrophages and their signaling pathways may be the key to discovering
new avenues for the treatment of optic neuritis.
The anti-inflammatory action of FAs results in RGC rescue as demonstrated previously [5], and is
concomitant with reduced optic nerve damage as observed here. Indeed, acute EAE is characterized
by inflammation-dependent optic nerve damage [56] and suppression of inflammatory processes
has been shown to protect the optic nerve from axonal demyelination [57]. Our finding that FAs
supplementation exerts a myelin-protective role in the optic nerve is in line with previous results
demonstrating that a combination of FAs, antioxidants, free radicals, and amino acids can effectively
decrease axon demyelination in the optic nerve or in the spinal cord [7].
Finally, our finding that FAs may counteract, at least in part, RGC dysfunction adds the most
conclusive evidence to the their use against optic neuritis. In fact, restored visual function is an
important sign of neuroprotective efficacy of diet supplements and only a few neuroprotectants
with antioxidant or anti-inflammatory activity seem to promote RGC survival with restoration
of visual function in models of ocular pathologies [8–10]. As shown here, MOG-treated mice are
characterized by reduced amplitude of the PhNR, which is almost prevented by FAs supplementation.
The PhNR is a negative-going wave following the b-wave of the cone response, it originates in the
inner retinal layer, and its amplitude is well-correlated with the thickness of the RGC layer, thus
providing a direct, objective assessment of the changes in RGC function with the consequent clinical
applications [25–27,29,58]. PhNR advantage is that can be recorded noninvasively using conventional
ERG together with the a- and b-waves thus enabling the function of middle and outer retinal layers to
be evaluated at the same time.
5. Conclusions
Taken together, the present evidence that FAs successfully ameliorate RGC dysfunction by acting
as a major anti-inflammatory compound can now offer new perspectives not only for implementing
our knowledge on the effectiveness of diet supplement in counteracting optic neuritis, but also for
eventually expanding a complementary nutritional intervention in MS.
As shown in the schematic representation of Figure 6, the present data demonstrate an ability of
FAs to preserve significantly visual dysfunction by substantially preventing RGC loss and restoring
optic nerve damage through a major anti-inflammatory action including an effect on macrophage
polarization. Future studies should be planned to establish the necessary doses of FAs needed to
achieve significant beneficial effects as well as to encourage the development and consumption of
foods and/or supplements rich in FAs.
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Figure 6. Schematic diagram depicting the role of FAs in the EAE model. MOG induces an immune
response resulting in macrophage infiltration. Infiltrating macrophages can acquire distinct phenotypes
M1 or M2, of which, M1 produces pro-inflammatory cytokines and activates inflammatory processes,
while M2 plays a role in the blockade of inflammation and promotes tissue repair. Both FAs-induced
inhibition of M1 phenotype (red arrows) and FAs-induced activation of M2 phenotype (green
arrows) concur to prevent inflammatory processes in the retina thus hampering optic nerve damage
and retinal ganglion cell (RGC) death, events that both participate to counteract electroretinogram
(ERG) dysfunction.
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